Abstract:Objective To evaluate the effect of Aluminum-Magnesium and Aspirin Tablets (Ⅱ) on the platelet aggregation function and gastrointestinal reaction for stable ischemic heart disease. Methods A total of 587 patients with stable ischemic heart disease requiring Aspirin and Clopidogrel dual antiplatelet aggregation treated in the Department of Cardiology, the First Affiliated Hospital of Chengdu Medical College from January 2015 to May 2016 were selected. They were divided into A, B, C group. 195 cases of group A were treated with Clopidogrel, 196 cases of group B were treated with Aspirin and Clopidogrel, and 196 cases of group C were treated with Aluminum-Magnesium and Aspirin Tablets (Ⅱ). The platelet aggregation rate, efficacy before and after 30 days′ treatment, incidence of adverse reactions were compared among the three groups. Results The platelet aggregation rate after 30 days′ treatment of the three groups were lower than that before treatment (P < 0.05). After treatment, the platelet aggregation rate among the three groups were statistically different (P < 0.05). After treatment, the platelet aggregation rate in group A was higher than that in group B and C (P < 0.01); while the platelet aggregation rate had no difference between group B or C (P > 0.05). The treatment effect of all groups of anginas had no statistically significant difference (P > 0.05). There was no significant difference in the incidence of cardiovascular adverse events among the three groups (P> 0.05). The incidence of gastrointestinal adverse reactions was lower in group C than that in groups A and B (P < 0.05). Conclusion Aluminum-Magnesium and Aspirin Tablets (Ⅱ) has good clinical efficacy in patients with stable ischemic heart disease, and have fewer gastrointestinal adverse reactions.
李璐 陈林 周鹏. 铝镁匹林片(Ⅱ)治疗稳定型缺血性心脏病的作用及不良反应[J]. 中国医药导报, 2018, 15(29): 58-61.
LI Lu CHEN Lin ZHOU Peng. Effects and adverse reactions of Aluminum-Magnesium and Aspirin Tablets (Ⅱ) on stable ischemic heart disease. 中国医药导报, 2018, 15(29): 58-61.